lunes, 7 de agosto de 2017

Buprenorfina / Buprenorphine

Agosto 7, 2017. No. 2773



Visite M_xico
Buprenorfina para el dolor crónico. Una revisión de su efectividad
Buprenorphine for Chronic Pain: A Review of the Clinical Effectiveness [Internet].
Source
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jan.
CADTH Rapid Response Reports.
Excerpt
Buprenorphine is an opioid analgesic available in Canada as transdermal patches and sublingual tablets (tablets also contain naloxone).1,2Buprenorphine/naloxone is indicated for substitution treatment in opioid drug dependence in adults whereas transdermal buprenorphine is indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment. Buprenorphine produces typical opioid agonist effects and in higher doses its agonist effects reach a ceiling and it can act as an antagonist. This property distinguishes it from morphine. It has high affinity for mu opioid receptors but only weakly activates them.3 For this reason, buprenorphine may be less likely to cause respiratory depression than full opioid agonists such as fentanyl or morphine.4 When buprenorphine is given concomitantly with other opioids, it antagonizes the effects of the other opioids by displacing them from the mu receptors. This can lead to withdrawal syndrome if buprenorphine is added to another opioid. If buprenorphine is withdrawn while the dose of the other opioid is being increased, it can increase the risk of overdose.3 The role of opioids in chronic cancer pain has been well established but their role and the relative effectiveness of opioids such as buprenorphine in the context of chronic non-cancer pain is unclear.
PDF
Uso y mal uso de agonistas opioides en la adicción a los opioides.
Use and misuse of opioid agonists in opioid addiction.
Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091.
Abstract
Although methadone (an opioid agonist) and buprenorphine (a partial opioid agonist) have evidence to support their use in treating opioid use disorder, they remain misunderstood and underutilized. In this article, we outline the risks and benefits of using these drugs as maintenance therapy in opioid-dependent patients.
Nuevos desarrollos en el manejo de la adicción a opioides. Impacto del implante subdérmico de buprenorfina
New developments in managing opioid addiction: impact of a subdermal buprenorphine implant.
Drug Des Devel Ther. 2017 May 10;11:1429-1437. doi: 10.2147/DDDT.S109331. eCollection 2017.
Abstract
Opioid addiction to prescription and illicit drugs is a serious and growing problem. In the US alone, >2.4 million people suffer from opioid use disorder. Government and pharmaceutical agencies have begun to address this crisis with recently released and revised task forces and medication-assisted therapies (MAT). For decades, oral or intravenous (IV) MATs have helped patients in their recovery by administration of opioid agonists (methadone, buprenorphine, oxycodone), antagonists (naltrexone, naloxone), and combinations of the two (buprenorphine/naloxone). While shown to be successful, particularly when combined with psychological counseling, oral and IV forms of treatment come with constraints and challenges. Patients can become addicted to the agonists themselves, and there is increased risk for diversion, abuse, or missed dosages. Consequently, long-acting implants have begun to be developed as a potentially preferable method of agonist delivery. To date, the newest implant approved by the US Food and Drug Administration (May 2016) is Probuphine®, which delivers steady-state levels of buprenorphine over the course of 6 months. Numerous studies have demonstrated its efficacy and safety. Yet, implants come with their own risks such as surgical site irritation, possible movement, and protrusion of implant out of skin. This review introduces the opioid abuse epidemic, examines existing medications used for therapy, and highlights Probuphine as a new treatment option. Costs associated with MATs are also discussed.
KEYWORDS: Probuphine®; addiction; buprenorphine; long-acting implant; medication-assisted therapy; opioids
Probufina® (implante de buprenorfina). Un candidato prometedor en la dependencia oipioide
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.
Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134. doi: 10.1177/2045125316681984. Epub 2016 Dec 19.
Abstract
Opioid dependence leads to physical dependence and addiction which finally results in profound medical, psychological and social dysfunction. One of the useful medications for opioid dependence is buprenorphine, the partial opioid agonist, which is used alone or in combination with naloxone. However, buprenorphine is the victim of its own success due to its illicit use and accidental poisoning in children. Also, buprenorphine typically requires daily self-administration and its effectiveness heavily depends on patient adherence. So, poor treatment adherence results in ineffective treatment manifesting as craving and withdrawal symptoms. Short-term use of buprenorphine in opioid dependence is also often followed by relapse. Buprenorphine when used sublingually often results in inadequate or fluctuating blood concentrations and poorer treatment retention compared with methadone. All of these led to the development of Probuphine®, a polymeric matrix composed of ethylene vinyl acetate and buprenorphine in the form of implants, that are implanted subdermally in office practice and deliver the active drug over 6 months. Buprenorphine release from such implant is fairly consistent, avoiding plasma peaks and troughs, and the implant is also reported to be safe. In this review article, we have highlighted these aspects of treatment of opioid addiction, stressing on the pharmacology of buprenorphine and Probuphine®, and relevant clinical trials addressing the efficacy and safety of Probuphine®. This sustained-release implantable formulation of buprenorphine has the potential to be a suitable alternative to daily or alternate day sublingual buprenorphine which can thereby eliminate the need for daily supervision, minimizing fluctuations in plasma concentrations, and allowing these patients to reduce clinic or pharmacy visits.
KEYWORDS: Probuphine®; addiction; buprenorphine; implant; opioid dependence

XIV Congreso Virtual Mexicano de Anestesiología 2017
Octubre 1-Diciembre 31, 2017
Información / Information
Like us on Facebook   Follow us on Twitter   Find us on Google+   View our videos on YouTube 
Anestesiología y Medicina del Dolor

52 664 6848905

jueves, 3 de agosto de 2017

Placebo

Agosto 3, 2017. No. 2769




  


Un condicionamiento clásico sin sugerencias verbales provoca analgesia placebo e hiperalgesia nocebo.
A Classical conditioning without verbal suggestions elicits placebo analgesia and nocebo hyperalgesia.
PLoS One. 2017 Jul 27;12(7):e0181856. doi: 10.1371/journal.pone.0181856. eCollection 2017.
Abstract
The aim of this study was to examine the relationships among classical conditioning, expectancy, and fear in placebo analgesia and nocebo hyperalgesia. A total of 42 healthy volunteers were randomly assigned to three groups: placebo, nocebo, and control. They received 96 electrical stimuli, preceded by either orange or blue lights. A hidden conditioning procedure, in which participants were not informed about the meaning of coloured lights, was performed in the placebo and nocebo groups. Light of one colour was paired with pain stimuli of moderate intensity (control stimuli), and light of the other colour was paired with either nonpainful stimuli (in the placebo group) or painful stimuli of high intensity (in the nocebo group). In the control group, both colour lights were followed by control stimuli of moderate intensity without any conditioning procedure. Participants rated pain intensity, expectancy of pain intensity, and fear. In the testing phase, when both of the coloured lights were followed by identical moderate pain stimuli, we found a significant analgesic effect in the placebo group, and a significant hyperalgesic effect in the nocebo group. Neither expectancy nor fear ratings predicted placebo analgesia or nocebo hyperalgesia. It appears that a hidden conditioning procedure, without any explicit verbal suggestions, elicits placebo and nocebo effects, however we found no evidence that these effects are predicted by either expectancy or fear. These results suggest that classical conditioning may be a distinct mechanism for placebo and nocebo effects.
PDF

Papel terapéutico del placebo: evolución de un nuevo paradigma en la comprensión de la investigación y la práctica clínica
Therapeutic Role of Placebo: Evolution of a New Paradigm in Understanding Research and Clinical Practice.
Pain Physician. 2017 Jul;20(5):363-386.
Abstract
Research into interventional techniques in managing chronic spinal pain continues to be challenging, mystifying, confusing, and biased. Insight, or lack thereof, into placebo and nocebo phenomena contributes mightily to these difficulties. Unfortunately, placebo-nocebo responses are the subject of numerous controversies and challenges from not only a research perspective, but also clinical perspective. While interventionalists consider the biggest threat to interventional pain management research is inappropriate and outdated interpretation of the data, a greater problem is the misuse of the placebo response in research, with the declaration that all and everything as a placebo effect: with a misinterpretation of the nature of the placebo the, associated conclusions can be inaccurate. Researchers have been aware of placeboand nocebo effects for decades, even though misunderstandings and misgivings continue to be seen in scientific studies. In simplistic terms, placebo and nocebo had been understood to indicate improving or worsening of symptoms that occur during treatment with placebo/nocebo drugs or modalities. However, research has demonstrated that such terminology does not necessarily reflect "true" placebo effect or nocebo response. These effects are based on numerous factors, including natural course of a disease, spontaneous remission, regression to the mean, and a multitude of other conceptual, explanatory, and moral challenges. In modern clinical research, a neutral substance called placebo has been mainly used as a comparison factor rather than being studied itself, while the nocebo response has only been minimally studied.A major misconception involves active placebo, a concept that has been extended beyond the administration of inert substances. The definition of active placebo of an active agent given to a patient, even though the pharmacologic action of the active agent is not known to be beneficial, has been converted to conveniently change many of the treatments which are effective on their own to be defined as placebos, often leading to conclusions that none of the interventions are effective. This review focuses on a multitude of controversies surrounding placebo and nocebo phenomena in research and clinical applications. The discussion includes a focus on unsolved, forgotten, and ignored features of placebo responses in medicine, and provides an appropriate understanding of placebo and nocebo phenomena in interventional pain management. To that effect, this review also describes therapeutic placebos, research with open placebos, and improvements in understanding clinical applications of present interventional pain management research.
KEYWORDS: Placebo effect; active control trials active placebos.; interventional techniques; nocebo response; placebo analgesia

Los mecanismos moleculares de las respuestas al placebo en la analgesia
EL PODER CURATIVO DE LA MENTE: EL EFECTO PLACEBO
Alberto Porras, Alberto del Arco, Gregorio Segovia y Rodrigo Martínez
El Comité Ejecutivo de la IASP insta a Venezuela a centrarse en el acceso a medicamentos para el dolor a la luz de escasez crítica
IASP Executive Committee Urges Venezuela to Focus on Access to Pain Medications in Light of Critical Shortages
As the leading global organization that brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain with the goal of improved pain relief worldwide, the International Association for the Study of Pain (IASP) has been made aware that difficult conditions in Venezuela have resulted in inadequate access to pain treatment.
Like us on Facebook   Follow us on Twitter   Find us on Google+   View our videos on YouTube 
Anestesiología y Medicina del Dolor

52 664 6848905

lunes, 31 de julio de 2017

Resultados a largo plazo después de las fracturas de escafoides distales: un seguimiento de 10 años


Long-Term Outcomes After Distal Scaphoid Fractures: A 10-Year Follow-Up

Fuente
Este artículo es originalmente publicado en:
De:
2017 Jul 18. pii: S0363-5023(16)30779-1. doi: 10.1016/j.jhsa.2017.06.016. [Epub ahead of print]
Todos los derechos reservados para:

Copyright © 2017 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.


Abstract
PURPOSE:
The aim of this study was to evaluate the functional, clinical, and radiological outcome 10 years after distal scaphoid fractures.
CONCLUSIONS:
From an 8- to 11-year perspective, patients with distal scaphoid fractures report normal self-assessed hand function as well as good wrist motion and strength. The risk for development of posttraumatic scaphotrapezium-trapezoid (STT) joint arthritis was low.
Copyright © 2017 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
Arthritis; CT; classification; outcome; scaphoid fracture
Resumen
PROPÓSITO:
El objetivo de este estudio fue evaluar el resultado funcional, clínico y radiológico 10 años después de las fracturas distales del escafoides.
CONCLUSIONES:
Desde una perspectiva de 8 a 11 años, los pacientes con fracturas de escafoides distal informan de la función normal de la mano autoevaluada, así como el buen movimiento y la fuerza de la muñeca. El riesgo de desarrollar artritis en la articulación escafo-trapecio-trapezoidal (STT) postraumática fue bajo.
Copyright © 2017 Sociedad Americana de Cirugía de la Mano. Publicado por Elsevier Inc. Todos los derechos reservados.
PALABRAS CLAVE:
Artritis; Tomografía computada; clasificación; resultado; Fractura de escafoides
PMID:  28733100   DOI: